4-amino-5-(3-phenyl-1H-pyrazol-5-yl)-4H-1,2,4-triazole-3-thiol | 366007-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-amino-5-(3-phenyl-1H-pyrazol-5-yl)-4H-1,2,4-triazole-3-thiol
• 英文别名: 4-amino-3-(3-phenyl-1H-pyrazol-5-yl)-1H-1,2,4-triazole-5-thione
• CAS: 366007-57-0
• 化学式: C₁₁H₁₀N₆S
• mdl: MFCD07364356
• 分子量: 258.307
• InChiKey: UUEYIWCAVXLFIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  alpha-氯乙酰苯 、 4-amino-5-(3-phenyl-1H-pyrazol-5-yl)-4H-1,2,4-triazole-3-thiol 以 乙醇 为溶剂， 反应 1.5h， 以74%的产率得到6-phenyl-3-(3-phenyl-1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
  参考文献：
  名称：

  新型STAT3途径抑制剂-含吡唑的1,2,4-三唑-[3,4- b ]噻二嗪的优化

  摘要：

  在1,2-，3,4-三唑并[3,4- b ]噻二嗪支架上的结构-活性关系研究在针对选择性STAT3途径抑制剂的HTS运动中确定，确定吡唑基和噻二嗪上的特定芳基取代是必要的活动。通过在噻二嗪上引入α-甲基来实现效力和代谢稳定性的改善。优化的化合物表现出抗增殖活性，磷酸化的STAT3水平降低以及对STAT3目标基因的影响。这些化合物代表了针对STAT3途径的进一步药物发现努力的起点。

  DOI：

  10.1016/j.bmcl.2016.06.017
• 作为产物：
  描述：

  二硫化碳 、 3-phenyl-1H-pyrazole-5-carbohydrazide 在 氢氧化钾 、 一水合肼 作用下， 以45%的产率得到4-amino-5-(3-phenyl-1H-pyrazol-5-yl)-4H-1,2,4-triazole-3-thiol
  参考文献：
  名称：

  Dhiman; Wadodkar; Patil, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2001, vol. 40, # 7, p. 640 - 643

  摘要：

  DOI：

文献信息

• 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US10618914B2

  公开（公告）日：2020-04-14

  Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

  本研究公开了选择性抑制 STAT3 通路而非 STAT1 通路并具有抗增殖活性的化合物。还公开了治疗以 STAT3 过表达为特征的癌症的方法，这些方法比其他疗法更安全。
• 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
  申请人：UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US11111253B2

  公开（公告）日：2021-09-07

  Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.

  本研究公开了选择性抑制 STAT3 通路而非 STAT1 通路并具有抗增殖活性的化合物。还公开了治疗以 STAT3 过表达为特征的癌症的方法，这些方法比其他疗法更安全。
• 6-ARYL-7-SUBSTITUTED-3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AS INHIBITORS OF THE STAT3 PATHWAY WITH ANTI-PROLIFERATIVE ACTIVITY
  申请人：UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20190100535A1

  公开（公告）日：2019-04-04

  Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
• 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as Inhibitors of the STAT3 Pathway with Anti-Proliferative Activity
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20200339602A1

  公开（公告）日：2020-10-29

  Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
• [EN] 6-ARYL-7-SUBSTITUTED-3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AS INHIBITORS OF THE STAT3 PATHWAY WITH ANTI-PROLIFERATIVE ACTIVITY<br/>[FR] 3-(1H-PYRAZOL-5-YL)-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES 6-ARYL-7-SUBSTITUÉES EN TANT QU'INHIBITEURS DE LA VOIE STAT3 AYANT UNE ACTIVITÉ ANTI-PROLIFÉRATIVE
  申请人：UNIV PITTSBURGH

  公开号：WO2016115455A2

  公开（公告）日：2016-07-21

  Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.